Struggling PharmaNet launches new flexible staffing service

By Gareth Macdonald

- Last updated on GMT

Related tags: São paulo

US CRO PharmaNet hopes its new trial staffing service will provide an additional revenue stream and help stave-off plummeting 2008 incomes and compensate for a series of painful contract cancellations.

The firm, which is being bought by investment group JLL Partners for around $250m (€199m), is trying to regain its financial footing after slumping to a net loss of $215m in last year after almost a third of its contracts were cancelled in the first eight months of the year as drugmakers worldwide trimmed budgets.

While the new staffing service, PharmaNet Resource Solutions (PRS), is undoubtedly a response to increasing demand for clinical trial professionals worldwide, it is also represents a way for the firm to mitigate against contract cancellations.

PRS’ new head, Susan Seroskie, said that the service offers “a strong management team and experienced clinical research professionals that provide clients practical, customised resource strategies to ensure their requirements are delivered on-time and with the appropriate level of experience​.”

Sean Larkin, senior vice president of PharmaNet’s US team said that: "With an enhanced personnel selection process and scaleable approach, we can ensure that talented professionals with the right credentials are available for functional outsourcing business models​."

PharmaNet’s latest move follows recent efforts to expand the scope of its wider trials offering with the establishment of a new base in Sao Paulo, Brazil. The office, which was opened last month, completed the firm’s Latin American network that includes Columbia, Peru, Mexico, Chile and Argentina.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more